The demographical and clinicopathological characteristics of patients who had FGFR oncogenic mutations
| ID | Subtype | Gender | Age | Stage | Treatment history [TKI (PFS)] | Gene | AAChange | AF | Concurrent alteration | AF_concurrent alt | CNV | Sample type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P1 | LUSC | M | 56 | NA | Chemo, radiotherapy | FGFR3 | c.746C>G(p.S249C) | 2.51% | − | − | − | Plasma |
| P2 | LUAC | F | 52 | IV | Gefitinib (21 m), chemo plus VEGFR ab (4 m), osimertinib (5 m), afatinib (5 m) | FGFR3 | c.742C>T(p.R248C), c.1138G>A(p.G380R) | 5.52%, 4.94% | EGFR c.2240_2257delTAAGAGAAGCAACATCTC (p.L747_P753delinsS), EGFR T790M | 4.3%, 1.3% | − | Plasma (post gefitinib) |
| P3 | LUSC | F | 66 | NA | Surgery | FGFR3 | c.746C>G(p.S249C) | 31.64% | − | − | − | FFPE |
| P4 | LUSC | M | 67 | NA | Chemo | FGFR3 | c.746C>G(p.S249C) | 33.33% | PTEN p.K147Rfs*6, PIK3CA amplification | 50% | 1.7 | FFPE |
| P5 | LUSC | M | 66 | IV | Treatment-naïve | FGFR3 | c.746C>G(p.S249C) | 36.85% | PIK3CA amplification | − | 2.08 | FFPE |
| P6 | LUAC | M | 74 | IV | Treatment-naïve | FGFR3 | c.746C>G(p.S249C) | 0.86% | PIK3R2 c.1117G>A(p.G373R) | 2.35% | − | Plasma |
| P7 | LUSC | F | 67 | NA | Treatment-naïve | FGFR3 | c.746C>G(p.S249C) | 17.34% | PIK3CA c.1633G>A(p.E545K), c.2176G>A (p.E726K) | 17.84%, 19.76% | − | FFPE |
| P8 | LUSC | F | 50 | NA | Treatment-naïve | FGFR3 | c.742C>T(p.R248C) | 0.67% | − | − | − | FFPE |
| P9 | LUSC | M | 77 | NA | Treatment-naïve | FGFR3 | c.742C>T(p.R248C) | 44.29% | − | − | − | FFPE |
| P10 | LUAC | M | 78 | IV | Chemo, VEGFR antibody | FGFR3 | c.742C>T(p.R248C) | 0.62% | KRAS c.35G>A(p.G12D), HRAS c.38G>T (p.G13V), PIK3CA amplification | 0.7%, 38.11% | 1.9 | FFPE |
| P11 | LUAC | M | 57 | NA | Surgery | FGFR3 | c.746C>G(p.S249C) | 1.42% | KRAS c.35G>A(p.G12D), PIK3CA c.3103G>A(p.A1035T) | 2.67%, 1.67% | − | FFPE |
| P12 | LUSC | F | 59 | NA | Treatment-naïve | FGFR3 | c.1138G>A(p.G380R) | 8.52% | − | − | − | Plasma |
| P13 | LUSC | M | 55 | NA | Treatment-naïve | FGFR3 | c.746C>G(p.S249C) | 15.18% | PIK3CA c.1633G>A(p.E545K) | 18.82% | − | FFPE |
| P14 | LUSC | M | 61 | NA | Treatment-naïve | FGFR3 | c.1118A>G(p.Y373C) | 87.37% | PIK3CA c.1633G>A(p.E545K) | 46.84% | − | FFPE |
| P55 | LUSC | M | 65 | NA | Chemo | FGFR2 | c.1975A>G(p.K659E) | 78.90% | PIK3CA amplification | − | 3.63 | FFPE |
| P56 | LUSC | M | 71 | IV | Treatment-naïve | FGFR2 | c.1977G>C(p.K659N) | 2.86% | − | − | − | FFPE |
| P57 | LUSC | M | 74 | NA | Treatment-naïve | FGFR2 | c.1977G>C(p.K659N) | 34.39% | PIK3CA c.3145G>C(p.G1049R) | 21.98% | − | Plasma |
| P58 | LUAC | F | 64 | NA | Chemo | FGFR2 | c.868T>C(p.W290R) | 17.12% | KRAS c.35G>T(p.G12V) | 19.49% | − | Plasma |
| P59 | LUAC | F | 78 | NA | Treatment-naïve | FGFR1 | c.1638C>A(p.N546K) | 3.15% | NRAS c.35G>A(p.G12D), NRAS c.182A>T (p.Q61L), PIK3CA c.2702G>T(p.C901F), c.323G>A(p.R108H), c.1357G>A(p.E453K), PTEN p.Y16X | 0.385%, 1.22%, 1.7%, 0.54%, 2.06%, 4.05% | − | FFPE |
LUAC, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; TKI, tyrosine kinase inhibitor; PFS, progression-free survival; NA, not available; AF, allele frequency; CNV, copy number variation.